Because we couldn't test 3,500 products alone.

New non-human primate data show Coave's ligand-conjugated suprachoroidal vector, coAAV-SCS, achieved up to 120-fold higher ...

A streamlined tomato pangenome has exposed genetic switches that shape fruit size, flavor-related chemistry, and resistance to fungal disease. By combining genomic variation from a cultivated tomato ...

Advancing ZAG-101 into the clinic marks Zag’s transition to a clinical stage company,” said Jason Cole, Chief Executive Officer of Zag Bio. “We are beginning in Type 1 diabetes, where there remains a ...

Indian researchers identified non-tuberculous mycobacteria from bovine clinical samples, finding Mycobacterium vaccae to ...

Silicon Valley 101 host Chen Qian set the core question for the third annual Alignment 2026 conference—scheduled for October 10–11, 2026—in ...

Proposed dates for the arrival of the first humans in the Americas span more than 100,000 years. At one end sits Cerutti, a site in California that Holen and colleagues dated to about 130,000 years ...

Cellectis (NASDAQ:CLLS) outlined plans to advance two preclinical in vivo gene-editing candidates for severe forms of dyslipidemia, targeting hypertriglyceridemia and hypercholesterolemia through ...

Ovarian cancer remains the deadliest of the gynecologic malignancies, a distinction earned not because it is the most common ...

Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no ...

Across repeat-dose GLP toxicology, tumorigenicity and biodistribution studies, ERNA-101 demonstrated a favorable nonclinical ...

Tuesday, Ernexa Therapeutics ( ERNA) said it has been selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa, where CEO Sanjeev Luther will present the company's oncology strategy ...